<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01203085</url>
  </required_header>
  <id_info>
    <org_study_id>INC-6603</org_study_id>
    <secondary_id>1U54NS065712-01</secondary_id>
    <nct_id>NCT01203085</nct_id>
  </id_info>
  <brief_title>Development of Charcot Marie Tooth Disease (CMT) Pediatric Scale for Children With CMT</brief_title>
  <acronym>INC-6603</acronym>
  <official_title>Development and Validation of CMT Pediatric Scale for Children With Charcot Marie Tooth</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Muscular Dystrophy Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College London Hospitals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sydney Children's Hospitals Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nemours Children's Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this project is to develop and test a Charcot Marie Tooth disease (CMT)
      Pediatric Scale for use in evaluation in natural history CMT study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project is to develop a new CMT Pediatric Scale (CMTPeds) for Children with CMT.
      Although there is a validated score (the CMTNS) which measures disease severity for CMT, it
      is not always applicable to children due to their limited ability to relay information about
      their symptoms. The CMTPeds scale is being developed and validated in order to measure
      disease severity in children and have outcome measures available for future clinical trials.
      Children (defined as 21 and under) being evaluated will be asked to perform functional tasks
      such as using stairs, walking in a hallway, and performing hand function tests. This
      information will be used to validate the CMTPeds score. It is important to have validated
      instruments to measure disease severity in childhood so these can be used with clinical
      treatment trials are available.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2010</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>CMT Peds Scale Part 1: Symptoms</measure>
    <time_frame>1 year</time_frame>
    <description>The CMT Peds Scale Symptoms include foot and hand symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CMT Peds Score Part 2: Foot and Ankle Involvement</measure>
    <time_frame>1 year</time_frame>
    <description>Foot and ankle involvement includes foot posture index, range of ankle dorsiflexion, foot drop present/absent, and whether or not difficulty heel/toe walking.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CMT Peds Scale Part 3: Hand dexterity</measure>
    <time_frame>1 year</time_frame>
    <description>Hand dexterity involves hand dexterity testing and the nine-hole peg test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CMT Peds Scale Part 4: Hand strength</measure>
    <time_frame>1 year</time_frame>
    <description>Hand strength includes grip strength, thumb-index pinch, and three point pinch.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CMT Peds Scale Part 5: Foot Strength</measure>
    <time_frame>1 year</time_frame>
    <description>Foot strength includes the strength of plantar- and dorsi-flexion, eversion, and inversion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CMT Peds Score Part 6: Sensation</measure>
    <time_frame>1 year</time_frame>
    <description>Sensation includes pinprick and vibration sensations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CMT Peds Scale Part 7: Balance</measure>
    <time_frame>1 year</time_frame>
    <description>Balance is assessed by the Bruininks-Oseretsky Test of Motor Proficiency, 2nd Edition (BOT-2).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CMT Peds Scale Part 8: Motor Function</measure>
    <time_frame>1 year</time_frame>
    <description>Motor function assessment includes long jump, 10 meter run/walk, stair climb, stair descend, and 6 minute walk test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate CMT Pediatric Scale (CMT Peds Scale) in CMT natural history study</measure>
    <time_frame>6 months to 1 year</time_frame>
    <description>The sections of the CMT Peds Scale which are found to be clinically/functionally useful after one year of analysis will be carried forward for all pediatric patients every 6 months to one year.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Charcot Marie Tooth Disease</condition>
  <arm_group>
    <arm_group_label>Pediatric patients</arm_group_label>
    <description>All patients 21 years of age and under who are enrolled in the 6601 study and have undergone the pediatric scale tests.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who are 21 years of age and under who are also enrolled in the 6601 study and have
        performed all tasks to complete the CMT Peds Scale will be recruited for participation.
        Participation entails allow the information collected in the 6601 study be used for
        validation in the current study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All patients MUST be seen in person at one of the participating centers for enrollment in
        this study.

          -  Children (&lt; 21 years of age)

          -  Known or probable inherited neuropathies classified as CMT1, CMT2, or CMT4

        Exclusion Criteria:

          -  Known diagnoses of acquired neuropathy including toxic (e. g. medication related
             neuropathies); metabolic (e.g. diabetic), immune mediated or inflammatory [acute
             inflammatory demyelinating polyradiculoneuropathy (AIDP) or chronic inflammatory
             demyelinating polyneuropathy (CIDP)] polyneuropathies; neuropathy related to
             leukodystrophy, congenital muscular dystrophy; and patients with severe general
             medical conditions.

          -  Entirely normal conduction velocities of upper and lower limbs as this suggests that
             the subject may not have a neuropathy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael E Shy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shawna M Feely, MS</last_name>
    <phone>319-384-6362</phone>
    <email>Shawna-Feely@uiowa.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tiffany Grider, MS</last_name>
    <phone>319-384-6362</phone>
    <email>Tiffany-Grider@uiowa.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carly Siskind, MS, LCGC</last_name>
      <phone>650-721-5588</phone>
      <email>csiskind@stanfordmed.org</email>
    </contact>
    <investigator>
      <last_name>John Day, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Connecticut</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gyula Acsadi, MD</last_name>
      <phone>860-837-7500</phone>
      <email>gacsadi@connecticutchildrens.org</email>
    </contact>
    <investigator>
      <last_name>Gyula Acsadi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Henry, MA</last_name>
      <phone>407-650-7604</phone>
      <email>Shannon.Henry@nemours.org</email>
    </contact>
    <investigator>
      <last_name>Richard Finkel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shawna M Feely, MS</last_name>
      <phone>319-384-6362</phone>
      <email>Shawna-Feely@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Michael E Shy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Bogue, MS, CGC</last_name>
      <phone>734-647-9224</phone>
      <email>boguelc@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Sindhu Ramchandren, MS, CGC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet Sowden</last_name>
      <phone>585-275-1267</phone>
      <email>janet_sowden@urmc.rochester.edu</email>
    </contact>
    <investigator>
      <last_name>David Herrmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabrina Yum, MD</last_name>
      <phone>215-590-1719</phone>
      <email>YUMS@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Sabrina Yum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Westmead</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Gabrael</last_name>
      <phone>+61 2 9845 1904</phone>
      <email>natalig1@chw.edu.au</email>
    </contact>
    <investigator>
      <last_name>Joshua Burns, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>C. Fondazione IRCCS Istituto Neurologico Carlo Besta</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Davide Pareyson, MD</last_name>
      <phone>(+39)02-23943001</phone>
      <email>davide.pareyson@istituto-besta.it</email>
    </contact>
    <investigator>
      <last_name>Davide Pareyson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Hospital of Neurology and Neurosurgery</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>WC1N 3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacky Molyneaux</last_name>
      <phone>+44 207 380 6852</phone>
      <email>j.molyneaux@ion.ucl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Mary Reilly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dubowitz Neuromuscular Centre</name>
      <address>
        <city>London</city>
        <state>UK</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hinal Patel</last_name>
      <phone>44 02079052608</phone>
      <email>hinal.patel@ucl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Francesco Muntoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Italy</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://rarediseasesnetwork.epi.usf.edu/INC/</url>
    <description>Inherited Neuropathies Consortium Website</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2010</study_first_submitted>
  <study_first_submitted_qc>September 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2010</study_first_posted>
  <last_update_submitted>September 12, 2017</last_update_submitted>
  <last_update_submitted_qc>September 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Michael Shy</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tooth Diseases</mesh_term>
    <mesh_term>Charcot-Marie-Tooth Disease</mesh_term>
    <mesh_term>Nerve Compression Syndromes</mesh_term>
    <mesh_term>Hereditary Sensory and Motor Neuropathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

